Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198993 | 0.83 | IKBKB (0.39) | GAAALDH1A1LMNAPOLBMAPT | |
| SCHEMBL2402669 | 0.81 | DRD1 (0.47) | GAAALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL5785398 | 0.78 | GAA (0.38) | GAAALDH1A1LMNAPOLBMAPT | |
| SCHEMBL842957 | 0.78 | SMN1; SMN2 (0.47) | GAAALDH1A1LMNAPOLBMAPT | |
| SCHEMBL23149673 | 0.73 | ILK (0.41) | ALPLALDH1A1CHEK1AKT2P2RX7 | |
| SCHEMBL28151206 | 0.73 | HSP90AA1 (0.45) | ALPLGAAALDH1A1LMNAPOLB | |
| SCHEMBL20722970 | 0.72 | AKT2 (0.42) | GAAALDH1A1LMNAMAPTCHEK1 | |
| SCHEMBL6932113 | 0.71 | TDP1 (0.52) | GAAALDH1A1LMNAMAPTFGFR1 | |
| SCHEMBL1057636 | 0.71 | AKT2 (0.66) | ALDH1A1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL4856665 | 0.70 | ALPL (0.58) | ALPLCA9GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678793-B2 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1908764-A1 | Azolo triazines and pyrimidines | Bristol-Myers Squibb Pharma Company (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-0915880-B1 | AZOLO TRIAZINES AND PYRIMIDINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252756-A1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY. | 2006-11-09 | — | — | US | disclosed |
| US-7094782-B1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1344779-B1 | Azolo-pyrimidines | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1049699-B1 | PYRAZOLOTRIAZINES AS CRF ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1344779-A1 | Azolo-pyrimidines | Bristol-Myers Squibb Pharma Company (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030008885-A1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-6358950-B1 | ADMINISTERING (1,5-A)-PYRAZOLO-1,3,5-TRIAZINE DERIVATIVES AS ANXIOLYTIC AGENTS AND ANTIDEPRESSANTS; CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; CARDIOVASCULAR, AUTOIMMUNE, NERVOUS SYSTEM, EATING, AND PSYCHOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313124-B1 | AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS USED FOR THERAPY OF ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC, NEUROLOGICAL DISORDERS AS WELL AS TREATMENT OF IMMUNOLOGICAL, CARDIOVASCULAR OR HEART-RELATED DISEASES | DUPONT PHARMACEUTICALS COMPANY | 2001-11-06 | — | — | US | disclosed |
| US-6191131-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-20 | — | — | US | disclosed |
| US-6136809-A | (1,5-A)-PYRAZOLO-PYRIMIDINES AND (1,5-A)-1,2,3-TRIAZOLO-PYRIMIDINES FOR TREATMENT OF CARDIOVASVULAR DISORDERS, STRESS AND PSYCHOLOGICAL DISORDERS WITH CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST | DUPONT PHARMACEUTICALS (US) | 2000-10-24 | — | — | US | disclosed |
| US-6124289-A | TREATING ANXIETY OR DEPRESSION IN MAMMALS | DUPONT PHARMACEUTICALS CO. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6060478-A | ANTIDEPRESSANTS | DUPONT PHARMACEUTICALS (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0915880-A1 | AZOLO TRIAZINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998003510-A1 | AZOLO TRIAZINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252756-A1 | Azolo triazines and pyrimidines | CRH, CRHR1, CRHR2 | ALPL 1510/4885CA9 4631/4885GAA 3664/4885 |
| US-20030008885-A1 | Azolo triazines and pyrimidines | CRH, CRHR1, CRHR2 | ALPL 1584/4885CA9 4634/4885GAA 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.